Introduction: Liver is a vital organ and mediates many cellular processes. Liver may be injured in diabetes. Metformin treatment shows a high potential to lower the risk of liver injury or to ameliorate its damage.
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INTRODUCTION:
Diabetes mellitus is considered as the most noncommunicable diseases affecting human, with increasing prevalence at global level 1 . Type 2 diabetes is the most prevalent form of diabetes, about 90% of all cases 2 . At global level, it has been estimated that the prevalence of diabetes was 2.8% in 2000 and expected to increase to 4.4% in 2030 3 .
Diabetes and liver injury have well established association 1 . The metabolism of carbohydrates is mainly controlled by liver. In case, glycogen has accumulated within the liver, it is expected to develop hepatomegaly and alterations in liver enzymes such as mild to moderately elevated aminotransferases 4 .
Amino transferases include aspartatealanine aminotransferase (ALT) and aspartate aminotransferase (AST) reflect the magnitude of liver injury and can be good indicators for non-alcoholic steatohepatitis(NASH) 5 .
Usually, diabetes is associated with increased levels of ALT and AST
1
. In their study, Erbey et al 6 reported that there were elevated levels of ALT in diabetic patients 7.8% compared to 3.8% in control subjects. Salmela et al 7 reported the findings of their study as increased levels of ALT among diabetics to be associated with increased BMI and poor glycemic control.
Belcher and Schernthaner 8 conducted a study to explore the hepatic influences of medicines used to treat diabetics. The authors depended on published randomized, double-blind studies which compared the impacts of metformin or a sulphonylurea, gliclazide, in the treatment of over 3700 patients with Type 2 diabetes. Study findings showed that pioglitazone lowered the mean levels of liver enzymesbetween 3 and 18%, gliclazidelower liver enzymes from 3 to 13%. Metformin treatment induced slight differences in liver enzymes.
The study of Ni et al 1 aimed to explore the differences in the means of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin in diabetics compared with control subjects. The levels of these proteins were within normal range in control groups. Diabetic group participants exhibited increased levels of ALT (18.5%), AST (14.8%)and bilirubin (4.9%). The results showed that the levels of ALT and AST were not significantly correlated with other study variables including age, family history of diabetes, mode of therapy or type of diabetes.
Dango et.al. 9 conducted a study to investigate the differences in the levels of liver function test among type 2 diabetic patients who are treating with metformin. The results showed that the level of AST and ALT were lower in study group compared with control group. The mean value differences between the study group and control of total bilirubin(TB) were not statistically significant. In another study, Lebovitz et al 10 showed no significant differences in the incidence of liver enzymes in patients treated with metformin in trials with 5000 patients. Another study conducted by Al-Mola and Ahmed 12 showed that the level of ALT was higher (p<0.05)in metformin treated diabetics, while the levels of AST and bilirubin did not show any changes. On the other hand, the study of Desiletset al 12 showed increased level of bilirubin in diabetic patient treated by metformin.
STUDY OBJECTIVES:
To explore the potential of metformin treatment in reducing the level of liver injury.
METHODS AND SUBJECTS:
The present study employed the retrospective study design to review the files of diabetic patients. Files were considered eligible for revision if liver function tests were included. Study variables included, but not restricted to, gender, age, duration of diabetes, metformin treatment, and liver function tests. Data were gathered from each file and entered to excel sheet. After all data had been gathered, data were analyzed using SPSS version 21. Several styles of statistical analyses were involved including descriptive statistics. The relationship between variables was examined using Chi-square test, and T test. Significance was considered if p< 0.05.
RESULTS:

Demographic and clinical characteristics of participants
As shown in table 1, the mean age of study participants was 62.95+ 11.98 years, a total of 33 (53.22%) of study participants were males (figure 1); duration of diabetes was 7.51+5.86 years, metformin was used as a diabetic therapeutic option by 41 (66.13%) (Figure 2) , the mean dose of metformin was 1617.32+694.49 mg, the mean level of AST was 16.01+7.79, the mean level of ALT was 18.500+8. The impact of metformin dose on study variables: As shown in table 2, using T test showed that metformin dose was associated significantly with the mean level of AST (p=0.001), ALT (p=0.001), bilirubin (p=0.001), duration of diabetes (p=0.001), and age (p=0.001).
Table 2: The impact of metformin dose on study variables
The differences in liver enzymes in groups without metformin and with metformin treatment: As shown in table 3 and figure 4, we used independent T test to examine the differences in the means of liver enzymes. No statistical differences were observed (p>0.05). Diabetes is a chronic disease and has been associated with liver injury 1 . Liver injury is reflected through several parameters including liver enzymes 4 . The present study was conducted to explore the potential of metformin treatment in reducing the level of liver injury. The levels of AST, ALT, and bilirubin were within normal range. This implies that measures of liver injury among diabetic patients do not indicate injured liver, and this may reflect the protective role of metformin. In this context, the findings of this study support previous studies which showed positive role of metformin in reducing liver injury 8 . However, other studies reported increased levels of liver enzymes among diabetic patients who were treated with metformin 1, 6, 7 . On the other hand, other studies reported decreased levels of liver enzymes in diabetic patients treated with metformin 9 . Taken together, no agreements in studies about the impact of metformin in liver injury, it seems that population variations in studies play an important role.
In another step of analysis, we examined the relationship between metformin dose and liver enzymes and found significant relationships (p=0.001) for all. It means that as the level of metformin increases, the level of liver injury is likely to decrease and this confirmed a protective role of metformin. Larger studies are required to confirm this finding. No significant differences in the levels of liver enzymes were obtained when the liver enzymes were compared in groups with metformin and without metformin treatment. This is again confirmed that metformin may act on long term to maintain the function of liver.
CONCLUSION: liver injury in diabetes is a long term process and the use of metformin can offer protection against liver injury through keeping liver enzymes within normal limits. 
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